echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tianyan Pharmaceutical's Phase Ib/II clinical trial of CTLA-4 mAb combined with pembrolizumab was approved by FDA

    Tianyan Pharmaceutical's Phase Ib/II clinical trial of CTLA-4 mAb combined with pembrolizumab was approved by FDA

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 16, Tianyan Pharmaceutical announced that the U.


    ADG126 safe antibody can achieve specific activation in the tumor microenvironment, enhance therapeutic effect through strong clearance of regulatory T cells, and maintain physiological function through flexible ligand blockade


    Using precise masking technology to cover the antigen-binding domain of antibodies, Tianyan's safe antibody technology can solve the safety and tolerability problems in many antibody therapies


    The ADG126-P001 clinical trial is designed to evaluate the safety, tolerability and recommended dose of Phase II clinical trials of ADG126 in combination with pembrolizumab.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.